Confidential treatment has been requested for portions of this Exhibit. The copy filed herewith omits the
information subject to the confidentiality request. Omissions are designated as [Intentionally Redacted]. A
complete version of this exhibit has been filed separately with the Securities and Exchange Commission.
DIAGNOSTIC AND DRUG PRODUCT MANUFACTURING, SUPPLY AND MARKETING
This Diagnostic and Drug Product Manufacturing, Supply and Marketing Agreement (the "Agreement") is made
and entered into as of the 10th day of May, 2004, by and between Spectrum Pharmaceuticals, Inc., a Delaware
corporation ("Spectrum") with its principal office at 157 Technology Drive, Irvine, California, USA, 92618, and
Shantha Biotechnics Pvt. Ltd., a private limited company organized under the laws of India ("Shantha") with its
principal office at Serene Chambers, 111rd Floor, Road No. 7, Banjara Hills, Hyderabad - 500 034, India.
A. Shantha currently manufactures Diagnostic Products and Biotech Products at its facilities in India. Shantha
possesses technologies and manufacturing capabilities that allow Shantha to manufacture such products with high
quality and at a low cost.
B. Spectrum possesses skills and experience in filing and processing applications for approval of drugs with the
FDA; and Spectrum also possesses skills and experience in marketing and distributing drugs, particularly in the
C. The parties share a belief that by working together they can successfully obtain regulatory approval for, and
thereafter market and distribute, many of Shantha's current and future products in the United States.
IN CONSIDERATION of the above recitals and the mutual covenants set forth below, the parties agree as
1. Definitions. The following terms will have the meanings given them below:
Act means the Federal Food, Drug and Cosmetic Act, as amended from time to time.
ARA means an application for regulatory approval submitted to the FDA